LCD/NCD Portal

 EXTERNAL INFUSION PUMPS L11555

 

 

Region IV

 

DME

Jurisdiction C

 

08/05/2011

 

• For any item to be covered by Medicare, it must

o Be eligible for a defined Medicare benefit category.

o Be reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member.

o Meet all other applicable Medicare statutory and regulatory requirements.

o For the items addressed in this local coverage determination, the criteria for "reasonable and necessary", based on Social Security Act § 1862(a) (1) (A) provisions, are defined by the following indications and limitations of coverage and/or medical necessity.

• For an item to be covered by Medicare a written signed and dated order must be received by the supplier before a claim is submitted.

o If the supplier bills for an item addressed in this policy without first receiving the completed order, the item will be denied as not reasonable and necessary.

• An external infusion pump is covered for the following indications (I-V):

o An infusion pump described by codes E0779, E0780, E0781, and E0791 is covered for indications I – III, V(A) – V(D), V(F), and V(G).

 Coverage of other pumps is addressed under indications IV, V (E), and V (H).

o Administration of deferoxamine for the treatment of chronic iron overload.

o Administration of chemotherapy for the treatment of primary hepatocellular carcinoma or colorectal cancer where this disease is unresectable or where the patient refuses surgical excision of the tumor.

 Anticancer chemotherapy drugs used in these conditions are not required to meet the criteria described by indication V, situation A.

o Administration of morphine when used in the treatment of intractable pain caused by cancer.

o Administration of continuous subcutaneous insulin for the treatment of diabetes mellitus (ICD-9 codes 249.00-250.93) if criterion A or B is met and if criterion C or D is met:

 C-peptide testing requirement – must meet criterion 1 or 2 and criterion 3:

• C-peptide level is less than or equal to 110 percent of the lower limit of normal of the laboratory's measurement method.

• For patients with renal insufficiency and a creatinine clearance (actual or calculated from age, weight, and serum creatinine) less than or equal to 50 ml/minute, a fasting C-peptide level is less than or equal to 200 per cent of the lower limit of normal of the laboratory’s measurement method.

• A fasting blood sugar obtained at the same time as the C-peptide level is less than or equal to 225 mg/dl.

 Beta cell autoantibody test is positive.

 The patient has completed a comprehensive diabetes education program, has been on a program of multiple daily injections of insulin (i.e., at least 3 injections per day) with frequent self-adjustments of insulin dose for at least 6 months prior to initiation of the insulin pump, and has documented frequency of glucose self-testing an average of at least 4 times per day during the 2 months prior to initiation of the insulin pump, and meets one or more of the following criteria (1 - 5) while on the multiple injection regimen:

• Glycosylated hemoglobin level (HbA1C) greater than 7 percent

• History of recurring hypoglycemia

• Wide fluctuations in blood glucose before mealtime

• Dawn phenomenon with fasting blood sugars frequently exceeding 200 mg/dL

• History of severe glycemic excursions

 The patient has been on an external insulin infusion pump prior to enrollment in Medicare and has documented frequency of glucose self-testing an average of at least 4 times per day during the month prior to Medicare enrollment.

o If criterion A or B is not met, the pump and related accessories, supplies, and insulin will be denied as not reasonable and necessary.

 If criterion C or D is not met, the pump and related accessories, supplies, and insulin will be denied as not reasonable and necessary.

o Continued coverage of an external insulin pump and supplies requires that the patient be seen and evaluated by the treating physician at least every 3 months.

 In addition, the external insulin infusion pump must be ordered and follow-up care rendered by a physician who manages multiple patients on continuous subcutaneous insulin infusion therapy and who works closely with a team including nurses, diabetic educators, and dieticians who are knowledgeable in the use of continuous subcutaneous insulin infusion therapy.

o Subcutaneous insulin is administered using ambulatory infusion pump E0784. Claims for usage of infusion pumps other than E0784 will be denied as not reasonable and necessary.

o Administration of other drugs if either of the following sets of criteria (1) or (2) are met:

 Criteria set 1:

• Parenteral administration of the drug in the home is reasonable and necessary.

• An infusion pump is necessary to safely administer the drug.

• The drug is administered by a prolonged infusion of at least 8 hours because of proven improved clinical efficacy.

• The therapeutic regimen is proven or generally accepted to have significant advantages over intermittent bolus administration regimens or infusions lasting less than 8 hours.

 Criteria set 2:

 Parenteral administration of the drug in the home is reasonable and necessary.

 An infusion pump is necessary to safely administer the drug.

 The drug is administered by intermittent infusion (each episode of infusion lasting less than 8 hours) which does not require the patient to return to the physician's office prior to the beginning of each infusion.

 Systemic toxicity or adverse effects of the drug is unavoidable without infusing it at a strictly controlled rate as indicated in the Physicians’ Desk Reference, or the U.S. Pharmacopeia Drug Information.

o Coverage for the administration of other drugs, based on criteria set (1) or (2), using an external infusion pump is limited to the following situations (A) - (H):

 Administration of the anticancer chemotherapy drugs cladribine, fluorouracil, cytarabine, bleomycin, floxuridine, doxorubicin (non-liposomal), vincristine or vinblastine by continuous infusion over at least 8 hours when the regimen is proven or generally accepted to have significant advantages over intermittent administration regimens.

 Administration of narcotic analgesics (except meperidine) in place of morphine to a patient with intractable pain caused by cancer that has not responded to an adequate oral/transdermal therapeutic regimen and/or cannot tolerate oral/transdermal narcotic analgesics.

 Administration of the following antifungal or antiviral drugs: acyclovir, foscarnet, amphotericin B, and ganciclovir.

 Administration of parenteral inotropic therapy, using the drugs dobutamine, milrinone and/or dopamine for patients with congestive heart failure and depressed cardiac function if a patient meets all of the following criteria:

• Dyspnea at rest or with minimal exertion is present despite treatment with maximum or near maximum tolerated doses of digoxin, a loop diuretic, and an angiotensin converting enzyme inhibitor or another vasodilator (e.g., hydralazine or isosorbide dinitrate), used simultaneously (unless allergic or intolerant)

• Doses are within the following ranges (lower doses will be covered only if part of a weaning or tapering protocol from higher dose levels):

o Dobutamine - - 2.5-10 mcg/kg/min

o Milrinone - - 0.375-0.750 mcg/kg/min

o Dopamine - - less than or equal to 5 mcg/kg/min

o Cardiac studies by either invasive hemodynamic technique or using thoracic electrical bioimpedance (impedance cardiography), performed within 6 months prior to the initiation of home inotropic therapy showing

 cardiac index (CI) is less than or equal to 2.2 liters/min/meter squared and/or pulmonary capillary wedge pressure (PCWP) is greater than or equal to 20 mm Hg before inotrope infusion on maximum medical management.

 at least a 20% increase in CI and/or at least a 20% decrease in PCWP during inotrope infusion at the dose initially prescribed for home infusion

 There has been an improvement in patient well-being, (less dyspnea, improved diuresis, improved renal function and/or reduction in weight) with the absence of dyspnea at rest at the time of discharge and the capability of outpatient evaluation by the prescribing physician at least monthly

 In the case of continuous infusion, there is documented deterioration in clinical status when the drug(s) is tapered or discontinued under observation in the hospital, or in the case of intermittent infusions, there is documentation of repeated hospitalizations for congestive heart failure despite maximum medical management

 Any life threatening arrhythmia is controlled prior to hospital discharge and there is no need for routine electrocardiographic monitoring at home

 The patient is maintained on the lowest practical dose and efforts to decrease the dose of the drug(s) or the frequency/duration of infusion are documented during the first 3 months of therapy

 The patient’s cardiac symptoms, vital signs, weight, lab values, and response to therapy are routinely assessed and documented in the patient’s medical record.

 Administration of epoprostenol (J1325) or treprostinil (J3285) for patients with pulmonary hypertension if they meet the following disease criteria:

• The pulmonary hypertension is not secondary to

o pulmonary venous hypertension

 (e.g., left sided atrial or ventricular disease, left sided valvular heart disease, etc.)

o disorders of the respiratory system

 (e.g., chronic obstructive pulmonary disease, interstitial lung disease, obstructive sleep apnea or other sleep disordered breathing, alveolar hypoventilation disorders, etc.)

• The patient has primary pulmonary hypertension or pulmonary hypertension which is secondary to one of the following conditions:

o connective tissue disease

o thromboembolic disease of the pulmonary arteries

o human immunodeficiency virus (HIV) infection

o cirrhosis

o diet drugs

o congenital left to right shunts

o Other.

 If these conditions are present, the following criteria must be met:

• The pulmonary hypertension has progressed despite maximal medical and/or surgical treatment of the identified condition

• The mean pulmonary artery pressure is greater than 25 mm Hg at rest or greater than 30 mm Hg with exertion

• The patient has significant symptoms from the pulmonary hypertension

o (i.e., severe dyspnea on exertion, and either fatigability, angina, or syncope)

• Treatment with oral calcium channel blocking agents has been tried and failed, or has been considered and ruled out.

o Epoprostenol/treprostinil is administered using ambulatory infusion pump K0455. Claims for usage of infusion pumps other than K0455 will be denied as not reasonable and necessary.

o Gallium nitrate (J1457) is covered for the treatment of symptomatic cancer-related hypercalcemia (ICD-9 275.42). In general, patients with serum calcium (corrected for albumin) less than 12 mg/dl would not be expected to be symptomatic.

o The recommended usage for gallium nitrate is daily for five consecutive days. Use for more than 5 days will be denied as not reasonable and necessary.

o More than one course of treatment for the same episode of hypercalcemia will be denied as not reasonable and necessary.

o Ziconotide (J2278) is covered for the management of severe chronic pain in patients for whom intrathecal (IT or epidural) therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or IT morphine.

o Subcutaneous immune globulin (J1559, J1561, J1562) is covered only if criteria 1 and 2 are met:

 The subcutaneous immune globulin preparation is a pooled plasma derivative which is approved for the treatment of primary immune deficiency disease; and

 The patient has a diagnosis of primary immune deficiency disease (ICD-9 codes 279.04, 279.05, 279.06, 279.12, 279.2).

• Coverage of subcutaneous immune globulin applies only to those products that are specifically labeled as subcutaneous administration products. Intravenous immune globulin products are not covered under this LCD.

• Only an E0779 infusion pump is covered for the administration of subcutaneous immune globulin. If a different pump is used, it will be denied as not reasonable and necessary.

 

• GENERAL

o External infusion pumps and related drugs and supplies will be denied as not reasonable and necessary when the criteria described by indication (I), (II), (III), (IV) or (V) are not met.

o When an infusion pump is covered, the drug necessitating the use of the pump and necessary supplies are also covered.

 When a pump has been purchased by the Medicare program, other insurer, or the patient, or the rental cap has been reached, the drug necessitating the use of the pump, and supplies are covered as long as the coverage criteria for the pump are met.

o An external infusion pump and related drugs and supplies will be denied as not reasonable and necessary in the home setting for the treatment of thromboembolic disease and/or pulmonary embolism by heparin infusion.

o An infusion controller device (E1399) is not reasonable and necessary.

o An IV pole (E0776) is covered only when a stationary infusion pump (E0791) is covered. It is considered not reasonable and necessary if it is billed with an ambulatory infusion pump (E0779, E0780, E0781, E0784, or K0455).

o Supplies for the maintenance of a parenteral drug infusion catheter (A4221) are covered during the period of covered use of an infusion pump.

 They are also covered for the weeks in between covered infusion pump use, not to exceed 4 weeks per episode.

o Supplies used with an external infusion pump, A4222 or K0552, are covered during the period of covered use of an infusion pump.

 Allowance is based on the number of cassettes or bags (A4222) prepared or syringes (K0552) used.

 For intermittent infusions, no more than one cassette or bag is covered for each dose of drug.

 For continuous infusion, the concentration of the drug and the size of the cassette, bag, or syringe should be maximized to result in the fewest cassettes, bags, or syringes in keeping with good pharmacologic and medical practice.

o Drugs and supplies that are dispensed but not used for completely unforeseen circumstances (e.g., emergency admission to hospital, drug toxicity, etc.) are covered.

 Suppliers are expected to anticipate changing needs for drugs (e.g., planned hospital admissions, drug level testing with possible dosage change, etc.) in their drug and supply preparation and delivery schedule.

• Charges for drugs administered by a DME infusion pump may only be billed by the entity that actually dispenses the drug to the Medicare beneficiary and that entity must be permitted under all applicable federal, state, and local laws and regulations to dispense drugs.

o Only entities licensed in the state where they are physically located may bill for infusion drugs.

o Drugs and related supplies and equipment billed by a supplier who does not meet these criteria will be denied as not reasonable and necessary.

 

 

Bill Type Codes:

• Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service.

• Absence of a Bill Type does not guarantee that the policy does not apply to that Bill Type.

• Complete absence of all Bill Types indicates that coverage is not influenced by Bill Type and the policy should be assumed to apply equally to all claims.

 

Revenue Codes:

• Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service.

• In most instances Revenue Codes are purely advisory; unless specified in the policy services reported under other Revenue Codes are equally subject to this coverage determination.

• Complete absence of all Revenue Codes indicates that coverage is not influenced by Revenue Code and the policy should be assumed to apply equally to all Revenue Codes.

 

 

CPT/HCPCS Codes

 

• The appearance of a code in this section does not necessarily indicate coverage.

 

HCPCS MODIFIERS:

 

EY – No physician or other licensed health care provider order for this item or service

 

GA – Waiver of liability statement issued as required by payer policy, individual case

 

GY - Item or service statutorily excluded or does not meet the definition of any Medicare benefit

 

GZ – Item or service expected to be denied as not reasonable and necessary

 

JB - Administered Subcutaneously

 

KX - Requirements specified in the medical policy have been met

 

HCPCS CODES:

 

EQUIPMENT

 

E0776 IV POLE

E0779 AMBULATORY INFUSION PUMP, MECHANICAL, REUSABLE, FOR INFUSION 8 HOURS OR GREATER

E0780 AMBULATORY INFUSION PUMP, MECHANICAL, REUSABLE, FOR INFUSION LESS THAN 8 HOURS

E0781 AMBULATORY INFUSION PUMP, SINGLE OR MULTIPLE CHANNELS, ELECTRIC OR BATTERY OPERATED, WITH ADMINISTRATIVE EQUIPMENT, WORN BY PATIENT

E0784 EXTERNAL AMBULATORY INFUSION PUMP, INSULIN

E0791 PARENTERAL INFUSION PUMP, STATIONARY, SINGLE OR MULTI-CHANNEL

E1399 DURABLE MEDICAL EQUIPMENT, MISCELLANEOUS

K0455 INFUSION PUMP USED FOR UNINTERRUPTED PARENTERAL ADMINISTRATION OF MEDICATION, (E.G., EPOPROSTENOL OR TREPROSTINOL)

 

SUPPLIES

 

A4221 SUPPLIES FOR MAINTENANCE OF DRUG INFUSION CATHETER, PER WEEK (LIST DRUG SEPARATELY)

A4222 INFUSION SUPPLIES FOR EXTERNAL DRUG INFUSION PUMP, PER CASSETTE OR BAG (LIST DRUGS SEPARATELY)

A4223 INFUSION SUPPLIES NOT USED WITH EXTERNAL INFUSION PUMP, PER CASSETTE OR BAG (LIST DRUGS SEPARATELY)

A4305 DISPOSABLE DRUG DELIVERY SYSTEM, FLOW RATE OF 50 ML OR GREATER PER HOUR

A4306 DISPOSABLE DRUG DELIVERY SYSTEM, FLOW RATE OF LESS THAN 50 ML PER HOUR

A9270 NON-COVERED ITEM OR SERVICE

A9274 EXTERNAL AMBULATORY INSULIN DELIVERY SYSTEM, DISPOSABLE, EACH, INCLUDES ALL SUPPLIES AND ACCESSORIES

K0552 SUPPLIES FOR EXTERNAL DRUG INFUSION PUMP, SYRINGE TYPE CARTRIDGE, STERILE, EACH

K0601 REPLACEMENT BATTERY FOR EXTERNAL INFUSION PUMP OWNED BY PATIENT, SILVER OXIDE, 1.5 VOLT, EACH

K0602 REPLACEMENT BATTERY FOR EXTERNAL INFUSION PUMP OWNED BY PATIENT, SILVER OXIDE, 3 VOLT, EACH

K0603 REPLACEMENT BATTERY FOR EXTERNAL INFUSION PUMP OWNED BY PATIENT, ALKALINE, 1.5 VOLT, EACH

K0604 REPLACEMENT BATTERY FOR EXTERNAL INFUSION PUMP OWNED BY PATIENT, LITHIUM, 3.6 VOLT, EACH

K0605 REPLACEMENT BATTERY FOR EXTERNAL INFUSION PUMP OWNED BY PATIENT, LITHIUM, 4.5 VOLT, EACH

 

DRUGS

 

J0133 INJECTION, ACYCLOVIR, 5 MG

J0285 INJECTION, AMPHOTERICIN B, 50 MG

J0287 INJECTION, AMPHOTERICIN B LIPID COMPLEX, 10 MG

J0288 INJECTION, AMPHOTERICIN B CHOLESTERYL SULFATE COMPLEX, 10 MG

J0289 INJECTION, AMPHOTERICIN B LIPOSOME, 10 MG

J0895 INJECTION, DEFEROXAMINE MESYLATE, 500 MG

J1170 INJECTION, HYDROMORPHONE, UP TO 4 MG

J1250 INJECTION, DOBUTAMINE HYDROCHLORIDE, PER 250 MG

J1265 INJECTION, DOPAMINE HCL, 40 MG

J1325 INJECTION, EPOPROSTENOL, 0.5 MG

J1455 INJECTION, FOSCARNET SODIUM, PER 1000 MG

J1457 INJECTION, GALLIUM NITRATE, 1 MG

J1559 INJECTION, IMMUNE GLOBULIN (HIZENTRA), 100 MG

J1561 INJECTION, IMMUNE GLOBULIN, (GAMUNEX-C/GAMMAKED), NON-LYOPHILIZED (E.G. LIQUID), 500 MG

J1562 INJECTION, IMMUNE GLOBULIN (VIVAGLOBIN), 100 MG

J1570 INJECTION, GANCICLOVIR SODIUM, 500 MG

J1817 INSULIN FOR ADMINISTRATION THROUGH DME (I.E., INSULIN PUMP) PER 50 UNITS

J2175 INJECTION, MEPERIDINE HYDROCHLORIDE, PER 100 MG

J2260 INJECTION, MILRINONE LACTATE, 5 MG

J2270 INJECTION, MORPHINE SULFATE, UP TO 10 MG

J2271 INJECTION, MORPHINE SULFATE, 100MG

J2275 INJECTION, MORPHINE SULFATE (PRESERVATIVE-FREE STERILE SOLUTION), PER 10 MG

J2278 INJECTION, ZICONOTIDE, 1 MICROGRAM

J3010 INJECTION, FENTANYL CITRATE, 0.1 MG

J3285 INJECTION, TREPROSTINIL, 1 MG

J7799 NOC DRUGS, OTHER THAN INHALATION DRUGS, ADMINISTERED THROUGH DME

J9000 INJECTION, DOXORUBICIN HYDROCHLORIDE, 10 MG

J9040 INJECTION, BLEOMYCIN SULFATE, 15 UNITS

J9065 INJECTION, CLADRIBINE, PER 1 MG

J9100 INJECTION, CYTARABINE, 100 MG

J9190 INJECTION, FLUOROURACIL, 500 MG

J9200 INJECTION, FLOXURIDINE, 500 MG

J9360 INJECTION, VINBLASTINE SULFATE, 1 MG

J9370 VINCRISTINE SULFATE, 1 MG

 

ICD-9 Codes that Support Medical Necessity

 

• The presence of an ICD-9 code listed in this section is not sufficient by itself to assure coverage.

• Refer to the section on “Indications and Limitations of Coverage and/or Medical Necessity” for other coverage criteria and payment information.

 

 

For HCPCS codes E0784, J1817:

 

249.00 - 249.91

SECONDARY DIABETES MELLITUS WITHOUT MENTION OF COMPLICATION, NOT STATED AS UNCONTROLLED, OR UNSPECIFIED - SECONDARY DIABETES MELLITUS WITH UNSPECIFIED COMPLICATION, UNCONTROLLED

250.00 - 250.93

DIABETES MELLITUS WITHOUT MENTION OF COMPLICATION, TYPE II OR UNSPECIFIED TYPE, NOT STATED AS UNCONTROLLED - DIABETES WITH UNSPECIFIED COMPLICATION, TYPE I [JUVENILE TYPE], UNCONTROLLED

 

 

For HCPCS code J1457:

 

275.42 HYPERCALCEMIA

 

 

For HCPCS code J1559, J1561, J1562

 

279.04 CONGENITAL HYPOGAMMAGLOBULINEMIA

279.05 IMMUNODEFICIENCY WITH INCREASED IGM

279.06 COMMON VARIABLE IMMUNODEFICIENCY

279.12 WISKOTT-ALDRICH SYNDROME

279.2 COMBINED IMMUNITY DEFICIENCY

 

 

Documentations Requirements

• Section 1833(e) of the Social Security Act precludes payment to any provider of services unless "there has been furnished such information as may be necessary in order to determine the amounts due such provider.”

o It is expected that the patient's medical records will reflect the need for the care provided.

o The patient's medical records include the physician's office records, hospital records, nursing home records, home health agency records, records from other healthcare professionals and test reports.

o This documentation must be available upon request.

• An order for each item billed must be signed and dated by the treating physician, kept on file by the supplier, and made available upon request.

o Items billed before a signed and dated order has been received by the supplier must be submitted with an EY modifier added to each affected HCPCS code.

• A DME Information Form (DIF) which has been completed, signed, and dated by the supplier, must be kept on file by the supplier and made available upon request.

o The DIF for External Infusion Pumps is CMS Form 10125. The initial claim must include an electronic copy of the DIF.

• If a patient begins using an infusion for one drug and subsequently the drug is changed or another drug is added, a Revised DIF must be submitted for use of the pump with the new or additional drug.

o In the case of an additional drug, all drugs for which the pump is used should be included on the Revised DIF.

• If information on an inotropic drug is requested, the supplier should submit a copy of the order and documentation from the treating physician, which includes information relating to each of the criteria (D1-D8), defined in the Indications and Limitations of Coverage section.

o This must include the before and after inotropic drug infusion values defined in D3. A suggested form for collecting this information is attached.

• Questions pertaining to medical necessity on any form used to collect this information may not be completed by the supplier or by anyone in a financial relationship with the supplier.

o If coverage criteria stated in the policy are not met, the claim should be accompanied by a copy of a letter from the physician giving details of the patient's history

 (e.g., dates of past hospitalization for heart failure, prior use of parenteral inotropic and the results, etc.).

o If invasive hemodynamic studies or impedance cardiography were not performed, the claim should be accompanied by a letter from the attending physician explaining the rationale for not performing the tests and accompanied by any other documentation deemed appropriate to explain this exception.

• If additional information on epoprostenol or treprostinil is requested, the supplier should submit signed and dated information from the treating physician stating the patient's diagnosis, the patient's current symptoms caused by pulmonary hypertension, and date and results of the pulmonary artery pressure.

o There must be a statement that the pulmonary hypertension is not secondary to pulmonary venous hypertension or a disorder of the respiratory system.

o There must be a statement of whether oral calcium channel blocking agents were tried and if so, the results, and if not, why a trial was not conducted.

 

• JB MODIFIER

o For all immune globulin (J1559, J1561, J1562) and associated infusion pump (E0779) claims where the route of administration is subcutaneous, a JB modifier must be added to each HCPCS code.

o For other methods of administration, no modifier should be added.

 

• KX, GA, GY and GZ MODIFIERS:

o For all claims for external insulin infusion pumps (E0784) and insulin (J1817), if the results of the patient's C-peptide level or beta cell autoantibody test meet the requirements outlined in section IV of the Coverage and Payment Rules, a KX modifier should be added to the HCPCS code.

o In the situation above describing use of the KX modifier, if all of the coverage criteria have not been met, the GA or GZ modifier must be added to the code.

 When there is an expectation of a medical necessity denial, suppliers must enter the GA modifier on the claim line if they have obtained a properly executed Advance Beneficiary Notice (ABN) or the GZ modifier if they have not obtained a valid ABN.

o Claims lines billed for the above services without a KX, GA, or GZ modifier will be rejected as missing information.

o An infusion drug not administered using a durable infusion pump must be billed using the appropriate HCPCS code plus the GY modifier.

o Refer to the Supplier Manual for more information on documentation requirements.

 

Sources of Information and Basis for Decision

 

A20210 - External Infusion Pumps - Policy Article - Effective January 2009

 

Home Parenteral Inotropic Therapy: Data Collection Form

 

External Infusion Pump DIF

 

Local Coverage Determination (LCD) for External Infusion Pumps (L11555)